# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from $1...
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(...
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...